Listing of Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I):



wherein:

R^1 is selected from the group consisting of:

(1) $-C_{1-6}$alkyl,

(2) $-C_{2-6}$ alkenyl,

(3) $-C_{0-6}$alkyl–C_{3-6} cycloalkyl,

(4)



, and

(5) heteroaryl selected from the group consisting of furyl, pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl,

wherein

(a) said alkyl, alkenyl or cycloalkyl is unsubstituted or substituted with one or more halogen, $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, hydroxy or cyano, and

(b) said heteroaryl is unsubstituted or substituted with one or more halogen, $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, phenyl, hydroxy or cyano,

and wherein R^{1a}, R^{1b}, R^{1c}, R^{1d} and R^{1e} are selected from the group consisting of:

(a) hydrogen,

(b) halogen,

(c) cyano,

(d) hydroxyl,

(e) $-C_{1-6}$ alkoxy,

(f) $-C(=O)-O-R^{7a}$,

(g) $-O-C_{0-6}alkyl-C(=O)-R^{7a}$,

(h) $-N-R^{7a}-S(O)_p-R^{7b}$,

or R^{1b} and R^{1c} are linked together to form $-O-CH_2-O-$ or $-CH=CH-CH=CH-$;

wherein said aryl is unsubstituted or substituted with one or more halogen, $-C_{1-6}alkyl$, $-C_{1-6}alkoxy$, hydroxyl or cyano;

R^2 is selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) $-C_{0-6}alkyl-Q^1-C_{1-6}alkyl$, wherein Q^1 is O or S,

(4) $-C_{1-6}alkyl$, and

(5) hydroxyl;

R^3 is selected from the group consisting of:

(1) hydrogen,

(2) $-C_{1-6}alkyl$,

(3) $-C_{0-6}alkyl-C_{3-6}cycloalkyl$,

(4) $-C_{0-6}alkyl-Q^2-C_{1-6}alkyl$, wherein Q^2 is O, S or -C(=O)-O-, and

(5)



,

(6) $-CH_2$-heteroaryl, wherein said heteroaryl is selected from the group consisting of furyl, pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl,

wherein said alkyl or cycloalkyl is unsubstituted or substituted with one or more

(a) halogen,
(b) $-C_{1-6}$alkyl,
(c) $-C_{2-6}$alkenyl,
(d) $-C_{1-6}$alkoxy,
(e) $-C_{6-10}$ aryl,
(f) hydroxyl, or
(g) cyano,

and said heteroaryl is unsubstituted or substituted with one or more

(a) $-C_{1-6}$alkyl,
(b) $-NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are selected from the group consisting of:
(i) hydrogen,
(ii) $-C_{1-6}$ alkyl,
(iii) $-C_{1-6}$alkyl$-C_{6-10}$ aryl, wherein said aryl can be substituted or unsubstited with halogen, cyano, C_{1-6} alkyl or C_{1-6} alkoxy, or
(iv) $-C_{1-6}$alkyl-$NR^{7a}R^{7b}$,

or N, R^{3f} and R^{3g} together form a 5 or 6 membered heterocyclic group, optionally containing an N, S or O atom in addition to the N atom attached to R^{3f} and R^{3g};

and R^{3a}, R^{3b}, R^{3c}, R^{3d} and R^{3e} are selected from the group consisting of:

(i) hydrogen,
(ii) halogen,
(iii) cyano,
(iv) hydroxyl,
(v) $-C_{1-6}$ alkyl,
(vi) $-O-R^{7a}$,
(vii) $-(C=O)-O-R^{8}$,
(viii) $-NR^{7a}- S(O)_p OR^{7b}$,
(ix) $-NR^{7a}- S(O)_p R^{7b}$,

(x) $-C_{0-6}$alkyl $-S(O)_m R^{7a}$,

(xi) $-C(=O)-NR^{7a}R^{7b}$,

(xii) $-C(=O)-R^8$

(xiii) $-NH-C(=O)-R^{7a}$,

(xiv) $-C_{0-6}$alkyl$-NR^{7a}R^{7b}$,

(xv) $-N_3$,

(xvi) $-NO_2$,

(xvii) C_{6-10} aryl, wherein said aryl can be unsubstituted or substituted with one or more

(A) halogen,

(B) cyano,

(C) $-C_{1-6}$ alkyl,

(D) $-C_{1-6}$ alkoxy,

(E) $-C(=O)-O-R^{7a}$,

(F) $-C(=O)-R^{7a}$,

(G) $-NR^{7a}R^{7b}$,

(H) $-NR^{7a}-S(O)_p-R^{7b}$,

(I) $-NR^{7a}-C(=O)-R^{7b}$,

(J) $-NO_2$

(xviii) heteroaryl selected from the group consisting of furyl,pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl,

wherein said heteroaryl is unsubstituted or substituted with one or more

(A) $-C_{1-6}$ alkyl, or

(B) $-C_{1-6}$ alkoxy;

or R^{3c} and R^{3d} are linked together to form phenyl or the group $-O-CH_2-O-$ or $-CH=CH-CH=CH-$;

or R^2 and R^3 are linked to form a carbocyclic ring (A):

(A)

wherein Q^3 is selected from the group consisting of:

(1) $-CR^{7a}R^{7b}-$,
(2) $-CR^{7a}R^{7b}CR^{7c}R^{7d}-$,
(3) $-CR^{7a}=CR^{7b}-$,
(4) $-CR^{7a}R^{7b}CR^{7c}R^{7d}CR^{7e}R^{7f}-$,
(5) $-CR^{7a}=CR^{7b}CR^{7c}R^{7d}-$, and
(6) $-CR^{7a}R^{7b}CR^{7d}=CR^{7e}-$;

R^4 is selected from the group consisting of:

(1) hydrogen,
(2) halogen,
(3) $-C_{1-6}$alkyl,
(4) $-C_{2-6}$alkenyl,
(5) $-C_{2-6}$alkynyl,
(6) phenyl,
(7) benzyl, and
(8) heteroaryl selected from the group consisting of furyl, pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl,
wherein said alkyl, alkenyl, alkynyl and phenyl is unsubstituted or substituted with one or more
(a) halogen,
(b) cyano,
(c) hydroxyl,
(d) phenyl,
(e) $-C_{1-6}$ alkyl,
(f) $-C_{1-6}$ alkoxy,
(g) $-C(=O)-O-R^{7a}$,
(h) $-C(=O)-R^{7a}$,
(i) $-NR^{7a}R^{7b}$,
(j) $-NR^{7a}-S(O)_p-R^{7b}$,
(k) $-NR^{7a}-C(=O)-R^{7b}$,
(l) $-NO_2$;

and said heteroaryl is unsubstituted or substituted with one or more:

(a) $-C_{1-6}$alkyl,

(b) $-C(=O)-O-R^{7a}$

(c) $-C(=O)-R^{7a}$

(d) $-NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} selected from the group consisting of

(i) hydrogen,

(ii) $-C_{1-6}$ alkyl,

(iii) $-C_{1-6}$alkyl–C_{6-10} aryl, wherein said aryl can be substituted or unsubstited with halogen, cyano, C_{1-6} alkyl or C_{1-6} alkoxy, or

(iv) $-C_{1-6}$alkyl–$NR^{7a}R^{7b}$;

or R^3 and R^4 may be joined together to form a 6-membered carbocyclic ring (B):

(B) 

provided that when R^3 and R^4 are joined together to form (B) then R^1 and R^2 are selected from the group consisting of hydrogen or C_{1-6} alkyl, and X^1, X^2, X^3, X^4, X^5 and X^6 are selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, cyano, alkylaryl or phenyl,

or R^3 and R^4 may be joined together to form a 7-membered carbocyclic ring (C):

(C) 

provided that when R^3 and R^4 are joined together to form (C) then R^1 and R^2 are selected from the group consisting of hydrogen, C_{1-6} alkyl or phenyl, or R^1 and R^2 can be linked together by the group $-CH_2CH_2CH_2CH_2-$; and Y^1, Y^2, Y^3, Y^4, Y^5 , Y^6, Y^7 and Y^8 are selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, cyano, alkylaryl or phenyl,

or R^1 and Y^5, or R^1 and Y^7, are linked together by $-CH_2-$,

or R^1 and Y^1, or Y^1 and Y^3, are linked together to form a phenyl or cyclopentyl ring;

R^{7a}, R^{7b}, R^{7c}, R^{7d}, R^{7e} and R^{7f} are selected from the group consisting of:

(1) hydrogen,
(2) C_{1-6} alkyl, and
(3) C_{6-10} aryl;

wherein said alkyl or aryl is unsubstituted or substituted with one or more halogen, $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, hydroxyl or cyano;

R^8 is selected from the group consisting of:

(1) hydrogen,
(2) C_{1-6} alkyl, and
(3) C_{6-10} aryl, wherein said aryl is unsubstituted or substituted with one or more halogen, $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, hydroxy or cyano;

n is 0, 1, 2 or 3
m is 0 or 1;
p is 1 or 2;
and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof.

2. (Original) The compound of Claim 1 wherein R^3 is selected from the group consisting of:

(1) $-C_{1-6}$alkyl,
(2) $-C_{0-6}$alkyl–C_{3-6}cycloalkyl,
(3)



, and

(4) $-CH_2$-heteroaryl, wherein said heteroaryl is selected from the group consisting of furyl, pyranyl, benzofuranyl, isobenzofuranyl, chromenyl, thienyl, benzothiophenyl, pyrrolyl,

pyrazolyl, imidazolyl, pyridyl,pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzimidazolyl, quinolyl and isoquinolyl.

3. (Original) The compound of Claim 2 wherein R^3 is



and n is 1.

4. (Original) The compound of Claim 2 wherein R^1 is



and m is 0.

5. (Original) The compound of Claim 4 wherein R^{1a}, R^{1b}, R^{1d} and R^{1e} are hydrogen, and R^{1c} is selected from the group consisting of halogen, C_{1-6} alkyl and C_{1-6} alkoxy.

6. (Original) The compound of Claim 2 wherein R^2 is hydrogen.

7. (Original) The compound of Claim 2 wherein R^4 is hydrogen.

8. (Original) The compound of Claim 1 which is a compound of formula (III)



(III)

9. (Original) The compound of Claim 8 wherein R^1 is



and m is 0.

10. (Original) The compound of Claim 9 wherein Q^3 is selected from the group consisting of
(1) $-CR^{7a}R^{7b}-$,
(2) $-CR^{7a}R^{7b}CR^{7c}R^{7d}-$, and
(3) $-CR^{7a}R^{7b}CR^{7c}R^{7d}CR^{7e}R^{7f}-$.

11. (Original) The compound of Claim 10 wherein R^{1d} is selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy and cyano, and R^{1a}, R^{1b}, R^{1c} and R^{1e} are hydrogen.

12. (Original) The compound of Claim 9 wherein R^{1b} and R^{1d} are selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} alkoxy and cyano, and R^{1a}, R^{1c} and R^{1e} are hydrogen.

13. (Original) The compound of Claim 8 wherein Q^3 is selected from the group consisting of $-CH_2CH_2-$ and $-CH2CH_2CH_2-$.

14. (Original) The compound of Claim 1 which is a compound of formula (IV)



(IV)

15. (Original) The compound of Claim 14 wherein R^1 and R^2 are hydrogen.

16. (Original) The compound of Claim 1 which is a compound of formula (V)



(V)

17. (Original) The compound of Claim 1 which is selected from the group consisting of















and pharmaceutically acceptable salts thereof.

18. (Original) The compound of Claim 1 which is selected from the group consisting of

Example	Structure
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	

Example	Structure
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	

Example	Structure
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	

Example	Structure
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	

Example	Structure
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	

Example	Structure
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	

Example	Structure
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	

Example	Structure
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	

Example	Structure
96	
97	
98	
99	
100	
101	
102	
103	
104	
105	
106	

Example	Structure
107	
108	
109	
110	
111	
112	
113	
114	
115	
116	
117	

Example	Structure
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	

Example	Structure
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	

Example	Structure
140	
141	
142	
143	
144	
145	
146	
147	
148	
149	
150	

Example	Structure
151	
152	
153	
154	
155	
156	
157	
158	
159	
160	
161	

Example	Structure
162	
163	
164	
165	
166	
167	
168	
169	
170	
171	
172	

Example	Structure
173	
174	
175	
176	
177	
178	
179	
180	
181	
182	
183	

Example	Structure
184	
185	
186	
187	
188	
189	
190	
191	
192	
193	
194	

Example	Structure
195	
196	
197	
198	
199	
200	
201	
202	
203	
204	
205	

Example	Structure
206	
207	
208	
209	
210	
211	
212	
213	
214	
215	
216	

Example	Structure
217	
218	
219	
220	
221	
222	
223	
224	
225	
226	
227	

Example	Structure
228	
229	
230	
231	
232	
233	
234	
235	
236	
237	
238	

Example	Structure
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	

Example	Structure
250	
251	
252	
253	
254	
255	
256	
257	
258	
259	
260	

Example	Structure
261	
262	
263	
264	
265	
266	
267	
268	
269	
270	

and pharmaceutically acceptable salts thereof.

19. (Original) The pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

20. (Original) A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

21. (Original) A method of inhibiting HIV protease in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

22. (Original) A method of treating infection by HIV in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

23. (Original) A method of treating AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.